Cost Effectiveness of Teriparatide for Postmenopausal Osteoporosis: A Systematic Review
Clinical Drug Investigation · 2026
DOI: 10.1007/s40261-026-01586-4 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Drug Investigation, 2026. Verfasst von Mohammad Alimoradnori und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Teriparatide, Osteoporosis, Postmenopausal, Bone Density Conservation Agents. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Iran University of Medical Sciences.
Abstract (Originalsprache)
Background
Postmenopausal osteoporosis is a major public health concern, imposing a substantial economic burden on healthcare systems. Teriparatide is one of the key pharmacological treatments; however, its cost effectiveness remains controversial.
Objective
This systematic review aimed to evaluate the cost effectiveness of teriparatide in the treatment of postmenopausal women with osteoporosis.
Methods
A comprehensive literature search was conducted in PubMed, Scopus, Embase, and Web of Science up to October 2024. The included studies comprised cost-effectiveness and cost-utility analyses conducted from healthcare system/payer and societal perspectives. Studies that met the inclusion criteria were assessed using the Quality of Health Economic Studies (QHES) checklist.
Results
A total of 22 economic evaluations were included. Most studies found that teriparatide was not cost effective under general conditions, except in specific scenarios such as reduced drug prices, the use of generic alternatives, or under sensitivity analysis assumptions. The variability in willingness-to-pay thresholds and regional drug costs contributed substantially to differing incremental cost-effectiveness ratio outcomes across countries. Only a few studies accounted for indirect costs, and the limited geographic distribution highlighted the need for research in underrepresented regions such as the Middle East and Africa. Furthermore, a funding disclosure analysis suggested a potential bias in industry-sponsored studies, although no definitive conclusions could be drawn.
Conclusions
Our findings suggest that teriparatide is generally not cost effective for the treatment of postmenopausal osteoporosis, although its economic value may vary depending on contextual and policy-related factors. Further robust economic evaluations are needed, incorporating both direct and indirect costs, and covering understudied regions. The findings of this review can support informed resource allocation and policy making in osteoporosis management. Limitations include heterogeneity across the included studies, potential language bias due to the inclusion of only English-language publications, and methodological variations that limited cross-study comparability
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran.
- Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran. abutorabi.a@iums.ac.ir.
- Department of Orthopedics, Bone and Joint Reconstruction Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
- Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran.
- Hospital Management Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran.
Förderung
- Iran University of Medical Sciences
Zitieren
APA
Alimoradnori, M., Abutorabi, A., Zabihiyeganeh, M., Arabloo, J., & Jahanghiri, R. (2026). Cost Effectiveness of Teriparatide for Postmenopausal Osteoporosis: A Systematic Review. Clinical Drug Investigation. https://doi.org/10.1007/s40261-026-01586-4
Vancouver
Alimoradnori M, Abutorabi A, Zabihiyeganeh M, Arabloo J, Jahanghiri R. Cost Effectiveness of Teriparatide for Postmenopausal Osteoporosis: A Systematic Review. Clinical Drug Investigation. 2026. doi:10.1007/s40261-026-01586-4
BibTeX
@article{Alimoradnori2026,
author = {Alimoradnori, Mohammad and Abutorabi, Ali and Zabihiyeganeh, Mozhdeh and Arabloo, Jalal and Jahanghiri, Reza},
title = {Cost Effectiveness of Teriparatide for Postmenopausal Osteoporosis: A Systematic Review},
journal = {Clinical Drug Investigation},
year = {2026},
doi = {10.1007/s40261-026-01586-4}
}
EUVIMED